David Cunningham REFERENCE: Abstract 3012, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 DAVID CUNNINGHAM, Royal Marsden Hospital, London The oral agent capeticabine
David Cunningham
REFERENCE: Abstract 3012, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007DAVID CUNNINGHAM, Royal Marsden Hospital, LondonThe oral agent capeticabine is just as effective as fluorouracil for treating patients whose metastatic colorectal cancer has relapsed. This is the finding of a study in which either agent was combined with oxaliplatin.David Cunninghamtold Peter Goodwin about his group’s findings reported at the ECCO conference.
Werner Scheithauer
Cetuximab With Irinotecan Slows Progression For Patients With Colorectal Cancer: The EPIC Trial
REFERENCE: Abstract 3003, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007WERNER SCHEITHAUER, Medical University of ViennaCOMMENT: DAVID CUNNINGHAM, Royal Marsden Hospital, LondonFor patients with metastatic colorectal cancer who have failed prior oxaliplatin therapy, cetuximab plus irinotecan could be the best treatment. This is according to a study that randomly assigned patients to irinotecan with or without cetuximab. Sarah Maxwell spoke to EPIC Trial authorWerner ScheithauerwhileDavid Cunninghamprovided comment.
Janice Dutcher
Sunitinib and Sorafenib: Expanded Access Data in Renal Cell Cancer
REFERENCE: 2007 Chemotherapy Foundation SymposiumJANICE DUTCHER, Our Lady of Mercy Medical Center, Bronx, NYEncouraging clinical benefits have emerged among patients with renal cell cancer treated with sunitinib and sorafenib who do not fulfill the usual criteria for clinical trials with these tyrosine kinase inhibitors.Janice Dutchertold Peter Godwin about findings from an “expanded access” program.
Robert Figlin
Pazopanib and Perifosine: New, Active Targeted Therapies in Renal Cancer
REFERENCE: 2007 Chemotherapy Foundation SymposiumROBERT FIGLIN, City of Hope Comprehensive Cancer Center, Los AngelesPazopanib and perifosine are two new agents that have performed well in phase II studies of renal cell carcinoma. Derek Thorne askedRobert Figlinabout the data on these drugs, and about what doctors should make of the increasing number of targeted therapies emerging for kidney cancer.
Gregory Wolf
IRX-II: A Novel Agent for Immune Modulation Therapy for Head and Neck Cancer
REFERENCE: 2007 Chemotherapy Foundation SymposiumGREGORY WOLF, University of Michigan, Ann ArborAn immune approach to treating cancer of the head and neck looks promising.Gregory Wolftold conference delegates at the Chemotherapy Foundation Symposium that clinical responses to a novel agent have been reported from Mexico, and that his group is now testing the same agent (IRX-II) in pilot studies. He talked with Peter Goodwin.
To subscribe to the ASCO Audio Journal of Oncology podcast please go toASCO Audio Journal of Oncology in Advance Presentationsorclick here.